Edwards Lifesciences Corporation $EW Shares Sold by Swedbank AB

Swedbank AB trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 27.6% in the first quarter, Holdings Channel reports. The firm owned 565,410 shares of the medical research company’s stock after selling 215,076 shares during the quarter. Swedbank AB’s holdings in Edwards Lifesciences were worth $40,981,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Quantbot Technologies LP acquired a new position in Edwards Lifesciences in the first quarter valued at approximately $26,000. Vega Investment Solutions acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $27,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the first quarter worth approximately $27,000. Global X Japan Co. Ltd. boosted its position in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after buying an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC boosted its position in shares of Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after buying an additional 205 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 0.7%

Shares of NYSE EW opened at $77.50 on Friday. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The business has a fifty day simple moving average of $78.92 and a 200-day simple moving average of $75.42. The company has a market cap of $45.50 billion, a price-to-earnings ratio of 11.15, a P/E/G ratio of 3.76 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the company posted $0.70 earnings per share. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,014 shares of company stock worth $1,698,844. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on EW shares. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Mizuho boosted their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Piper Sandler boosted their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Dbs Bank upgraded Edwards Lifesciences to a “hold” rating in a research report on Monday, June 2nd. Finally, Barclays upped their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.26.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.